This is a discussion on TA70: Leukaemia (chronic myeloid) - imatinib within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Leukaemia (chronic myeloid) - imatinib. It links to the published guidance and key ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
![]() |
| Thread Tools | |
| Display Modes | |
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA86: Gastro-intestinal stromal tumours (GIST) - imatinib | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA119: Leukaemia (lymphocytic) - fludarabine | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA174: Leukaemia (chronic lymphocytic, first line) - rituximab | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA174: Leukaemia (chronic lymphocytic, first line) - rituximab | industry_news | Updates from the Technology Assessment Authorities | 0 | 07-21-2009 08:58 PM |
| One Third of CML Patients Need Alternative to Imatinib | industry_news | Other Clinical Pharmacy News | 0 | 07-17-2008 02:59 PM |